

**RECEPTOR BASED RADIOLIGANDS FOR
NEUROIMAGING**

PREETI JHA



**DEPARTMENT OF CHEMISTRY
INDIAN INSTITUTE OF TECHNOLOGY DELHI
MARCH 2019**

© Indian Institute of Technology Delhi (IITD), New Delhi, 2019

**RECEPTOR BASED RADIOLIGANDS FOR
NEUROIMAGING**

by

PREETI JHA

Department of Chemistry

Submitted

**in the fulfillment of the requirements of the degree of Doctor of Philosophy
to the**



INDIAN INSTITUTE OF TECHNOLOGY DELHI

MARCH 2019

CERTIFICATE

This is to certify that the thesis entitled, “**RECEPTOR BASED RADIOLIGANDS FOR NEUROIMAGING**” being submitted by **Ms. PREETI JHA** to the Indian Institute of Technology Delhi, for the award of the degree of **Doctorate of Philosophy** in Chemistry, is an authentic record of research work carried by her. She has worked under my guidance and supervision. She has fulfilled the requirements for the submission of this thesis, which to my knowledge has reached the requisite standards.

The work and results embodied in this thesis have not been submitted, in part or in full, to any other institute or university for the award of any degree or diploma.

Dr. Nidhi Jain

Associate Professor

Department of Chemistry

Indian Institute of Technology Delhi

New Delhi - 110016

Dr. Anil Kumar Mishra

Scientist ‘G’, Addl. Director

Institute of Nuclear Medicine and

Allied Science, DRDO

Delhi - 110054

ACKNOWLEDGEMENTS

PhD is all about learning. The more you fail, the more you gain and the more you are challenged, the more you explore. The best lesson of being a Research Scholar is to learn to apply the basic concepts of life into Science and Development. Many ingredients of healthy living are inculcated during the entire training of PhD, especially perseverance, determination, dedication and preeminent of all the broad vision to convert the feeling of “cannot do this” to “did it”. Certainly, PhD Scholar has to strive hard and is awarded with the degree of Doctor of Philosophy, yet I believe that, it is the conclusion of cumulative efforts made by Supervisors, Mentors, Well-wishers, Friends and Family.

This journey would not have been accomplished without the guidance and energetic support of my Co-Supervisor, Dr. Anil Kumar Mishra, Scientist ‘G’, MIRC, Additional Director, INMAS. He has provided me all the freedom and a well-equipped platform to explore the possible avenues of Chemistry and Bioinformatics in Molecular Imaging. I express my deepest gratitude to him for his constant encouragements on the research as well as career. Some of his punch-line like “kuch pane ke liye uske piche padna hota hai”, has always kept me motivated to work hard.

The heartiest and spirited appreciation is expressed to my Supervisor, Dr. Nidhi Jain, Associate Professor, Department of Chemistry, IIT D, for her continuous support and catalytic recommendations throughout my PhD tenure. Her thoughtful and motivating persona have helped me to sustain the vulnerable times and inspired me to do better. Her extended support in finishing the Chemistry and Bioinformatics part of my thesis helped to compile the entire work, without which it would not have been possible to complete the course. I would also like to thank her for pouring a sense of trust and believe in me as well as teaching a beautiful essence of faith and appreciation, which I would always like to follow throughout my life.

The similar sincere acknowledgement goes to Dr. Shubhra Chaturvedi, Scientist 'E', DCRS at INMAS for her unconditional guidance, support, encouragement, insightful comments and critics and the scientific discussions. I would also like to thank her for not only improving my writing and presentation skills but also for grooming me as an independent researcher.

I am equally thankful to Dr. Ankur Kaul (DCRS, INMAS) for extending her friendly, kind hearted and appreciative support both as a friend as well as a tutor throughout my PhD curriculum, which helped to complete the work within the stipulated time.

The most sincere gratitude extends to Dr. A. K. Singh, Director, INMAS, Prof. V. Ramgopal Rao, Director, IIT D and Prof. Ravi Shankar, Head, Department of Chemistry, IIT D for providing me the opportunity to explore their departments and avail the necessary facilities.

I would also like to thank my SRC committee members, Prof. S. K. Khare, Prof. Shashank Deep and Prof. Veena Kaul for their thoughtful insights, which persuaded me to understand a broad spectrum of my work.

I am gratefully acknowledged to the Ministry of Defence, Defence Research and Development Organisation (DRDO) for providing the financial support for my research work.

Special vote of thanks is credited to Dr. Puja Panwar Hazari, Dr. Sweta Singh, Dr. Rashi Mathur, Dr. Pritesh, Dr. Ravi, Dr. Anjani K. Tiwari, Dr. Anupama Datta, Dr. Dipti K. Thukral, Dr. Raunak Varshney and Dr. Aruna Kaushik for their expert advices and providing a knowledge oriented surroundings.

I would like to express my hearty gratitude to Dr. Vikrant Atri, Assistant Professor, ANDC, DU and Prof. D. S. Rawat, Department of Chemistry, DU, who wonderfully inspired me to explore my career in Research and Development.

I am also thankful to the technical and administrative staff members of INMAS and IIT D for their help and cooperation.

A very special appreciation goes to Danish Equbal, CDRI, Pranav Pandey, INMAS, Ruchika Bhat and Pradeep Pant, IIT D and Dr. Nishant Roy, Swapnil Mishra, Ankesh Kumar, Vijay, Dr. Meena Bisht, Dr. Plawan K. Jha, Dr. Kanchan Chauhan and Dr. Divya for their unconditional support, friendship and care to achieve my goals.

I have had a great pleasure while working with my lab members of INMAS: Dr. Harleen, Viren, Ambika, Dr. Surbhi, Dr. Pallavi, Neelam, Swastika, Shweta, Anju, Deepa and Vishakha and Awadh, Sandeep, Poonam, Alankrita, Shyam, Shailendra, Himanshu, Ritu and Rajat at IIT D. Their companionship not only imprinted great memories but also rendered a healthy and fun-loving working environment.

I offer my soul gratitude to my siblings Prabhat K. Jha, Advocate Kamini Jha and Prakash C. Jha for being loving, caring, supportive, encouraging and a source of immense pleasure, happiness and peace on the verge of finishing my PhD.

Words are very limited to deliver my proud and grateful feelings for my parents: Advocate Arun K. Jha and Advocate Veena Jha, who have been the ultimate source of satisfaction and the pillars of my strength. I am immensely obliged to them for educating and nurturing me with an essence of love and for making uncountable sacrifices for the sake of my career. I whole heartedly dedicate this thesis to MY FAMILY.

Last but not the least, I devote all my achievements to the “GOD: the origin of life”.

Preeti Jha

ABSTRACT

Chapter 1: An overview of the need of neuroimaging and the importance of CADD for neuroreceptor specific drug development have been elucidated. Implications of 5-HT_{1A} and 5-HT₇ neuroreceptors in neurological disorders and the utilization of radioligands for early diagnostics have also been discussed.

Chapter 2: A brief description of computational methodology and various techniques employed to accomplish the entitled work have been provided.

Chapter 3: The 3D homology models of monomeric 5-HT_{1A} and 5-HT₇ receptors have been generated and validated. Mono-template methodology was conceived for developing 5-HT_{1A} receptor homology models, while multi-template approach was utilized for building the homology models of 5-HT₇ receptors. 3D4S derived mono-template models were found most promising and efficient for drug design and development.

Chapter 4: The 3D-structure of homodimeric 5-HT_{1A}-5-HT_{1A}, 5-HT₇-5-HT₇ and 5-HT_{1A}-5-HT₇ heterodimeric receptors have been generated using protein-protein docking and validated successfully. The dimer interface 1 (TM1/TM2/TM7/H8-ECL1) was found most stable and conserved for homo and heterodimerization of 5-HT_{1A} and 5-HT₇ receptors.

Chapter 5: Mixed affinity based monovalent and bivalent neuroimaging probes were designed by employing the SBDD approach of CADD. Receptor targeting ability of newly designed probes were predicted using Docking studies and analysed by investigating the receptor-ligand interactions at the recognition sites of monomeric dimeric receptor models. Drugability and dynamic stability at physiological conditions have also been studied.

Chapter 6: Synthesis, radiolabelling studies and pre-clinical bio-evaluations of the designed neuroimaging probes have been discussed in this chapter. Biocompatibility, *in vitro* stability, BBB permeation, non-invasive *in vivo* imaging and blood kinetics evaluations were performed to predict the applicability for medical imaging purposes. The *ex vivo* biodistribution and

regional brain uptake studies were also investigated to determine the organ distribution and specific localization of developed radioligands in the receptor-rich regions of brain.

Chapter 7: Leading outcomes of the entitled thesis, limitations and solutions, failure and merit, the future aspects and the scope of the thesis have been summarised.

सार

अध्याय 1: न्यूरोइमेजिंग की आवश्यकता का अवलोकन और न्यूरोरेसेप्टर विशिष्ट दवा विकास के लिए CADD के महत्व को स्पष्ट किया गया है। न्यूरोलॉजिकल विकारों में 5-HT_{1A} और 5-HT₇ न्यूरोरेसेप्टर्स के कार्यान्वयन और शुरुआती निदान के लिए रेडिओलिगेण्ड्स के उपयोग पर भी चर्चा की गई है।

अध्याय 2: कम्प्यूटेशनल कार्यप्रणाली और आवश्यक कार्य को पूरा करने के लिए नियोजित विभिन्न तकनीकों का संक्षिप्त विवरण प्रदान किया गया है।

अध्याय 3: मोनोमेरिक 5-HT_{1A} और 5-HT₇ रिसेप्टर्स के 3D होमोलॉजी मॉडल उत्पन्न और मान्य किए गए हैं। 5-HT_{1A} रिसेप्टर होमोलॉजी मॉडल विकसित करने के लिए मोनो-टेम्पलेट दृष्टिकोण की कल्पना की गई थी, जबकि 5-HT₇ रिसेप्टर्स के होमोलॉजी मॉडल के निर्माण के लिए मल्टी-टेम्पलेट दृष्टिकोण का उपयोग किया गया था। 3D4S व्युत्पन्न मोनो-टेम्पलेट मॉडल दवा डिजाइन और विकास के लिए सबसे आशाजनक और कुशल पाए गए।

अध्याय 4: होमोडायमेरिक 5-HT_{1A}-5-HT_{1A}, 5-HT₇-5-HT₇ और 5-HT_{1A}-5-HT₇ हेटेरोडायमेरिक रिसेप्टर्स की 3 डी संरचना प्रोटीन-प्रोटीन डॉकिंग का उपयोग करके उत्पन्न की गई है और सफलतापूर्वक सत्यापित की गई है। डायमर इंटरफ़ेस 1 (TM1 / TM2 / TM7 / H8-ECL1) को सबसे अधिक स्थिर और 5-HT_{1A} और 5-HT₇ रिसेप्टर्स के होमो और विषमकरण के लिए संरक्षित किया गया था।

अध्याय 5: मिश्रित आत्मीयता पर आधारित मोनोवैलेन्ट और बाइवैलेंट न्यूरोइमेजिंग प्रोब को CADD के SBDD दृष्टिकोण को नियोजित करके डिजाइन किया गया था। नए डिजाइन किए गए प्रोब की रिसेप्टर लक्ष्यीकरण क्षमता की भविष्यवाणी डॉकिंग अध्ययनों का उपयोग करके की गई थी और मोनोमेरिक डायमेरिक रिसेप्टर मॉडल के मान्यता स्थलों पर रिसेप्टर-लिगेण्ड इंटरैक्शन की जांच करके इसका विश्लेषण किया गया था। शारीरिक स्थितियों में दवा की क्षमता और गतिशील स्थिरता का भी अध्ययन किया गया है।

अध्याय 6: इस अध्याय में सिंथेसिस, रेडियोलेबलिंग अध्ययन और डिजाइन किए गए न्यूरोइमेजिंग एजेंटों के पूर्व-नैदानिक जैव मूल्यांकन पर चर्चा की गई है। जैव इमेजिंग, इन विट्रो स्थिरता, बीबीबी पारगम्यता, गैर-इनवेसिव इन-विवो इमेजिंग और रक्त काइनेटिक्स मूल्यांकन चिकित्सा इमेजिंग उद्देश्यों के लिए प्रयोज्यता की भविष्यवाणी करने के लिए किए गए थे। मस्तिष्क के रिसेप्टर-समृद्ध क्षेत्रों में विकसित रेडिओलिगेण्ड्स के वितरण और विशिष्ट स्थानीयकरण का निर्धारण करने के लिए पूर्व विवो बायोडिस्ट्रिब्यूशन और क्षेत्रीय मस्तिष्क उत्थान अध्ययनों की भी जांच की गई थी।

अध्याय 7: हकदार थीसिस, सीमाओं और समाधान, विफलता और योग्यता के प्रमुख परिणामों, भविष्य के पहलुओं और थीसिस के दायरे को संक्षेप में प्रस्तुत किया गया है।

TABLE OF CONTENT

<i>Certificate</i>	<i>i</i>
<i>Acknowledgements</i>	<i>iii</i>
<i>Abstract</i>	<i>vii</i>
<i>Table of Content</i>	<i>ix</i>
<i>List of Figures</i>	<i>xvii</i>
<i>List of Tables</i>	<i>xxxi</i>
<i>List of Schemes</i>	<i>xxxv</i>
<i>Glossary of Symbols and Abbreviations</i>	<i>xxxvii</i>
Chapter 1: Introduction	
1.1 Neuroimaging	1
1.2 Global health and neurological disorders	1
1.3 Diagnostics	2
1.3.1 Positron Emission Tomography (PET)	4
1.3.2 Single Photon Emission Computed Tomography (SPECT)	5
1.3.3 PET/SPECT for neuroimaging	8
1.4 Drug design and development	10
1.5 Homology Modeling (HM)	13
1.6 Neuroreceptors	15
1.6.1 Ionotropic receptors	16
1.6.2 Metabotropic receptors	16
1.6.3 GPCRs in psychiatric and neurological disorders	18
1.6.4 5-HT receptors	22

1.6.4.1	5-HT _{1A} receptor localization	23
1.6.4.2	5-HT ₇ receptor localization	24
1.7	Depression, Anxiety and Stress (DAS)	25
1.7.1	Biology of DAS: The HPA axis	26
1.7.2	Corticosterone mediated chronic stress/depression model	29
1.7.3	Pharmacological implications of 5-HT _{1A} /5-HT ₇ Rs	30
1.8	Radiopharmaceuticals	33
1.8.1	Introduction of radioisotope into BM	35
1.8.2	Diagnostic radionuclides	39
1.8.3	Carbon-11	39
1.8.4	Technitium-99m	43
1.9	Motivation and outline of the thesis	50
1.10	References	54
Chapter 2: Experimental Section		
2.1	Computational approach	73
2.2	Homology modeling	74
2.2.1	Selection of template	74
2.2.2	Sequence alignment	74
2.2.3	Building of models	75
2.2.3.1	Monomeric models of h5-HT _{1A} R and h5-HT ₇ R	75
2.2.3.2	Dimeric models of h5-HT _{1A} R/h5-HT ₇ R	75
2.3	Quality assessment	76
2.4	Docking	76
2.4.1	Validation of homology models	77
2.4.1.1	Monomeric h5-HT _{1A} R	77

2.4.1.2	Monomeric h5-HT ₇ R	78
2.4.2	Receptor-ligand interaction analysis	78
2.5	Embrace minimization	79
2.6	MM/GBSA	79
2.7	MD simulations	80
2.7.1	Validation of homology models	80
2.7.1.1	h5-HT _{1A} R	80
2.7.1.2	h5-HT ₇ R	81
2.7.2	Stability of dimeric h5-HT _{1A} R/ h5-HT ₇ R models	82
2.7.3	Complexes of designed monovalent/bivalent ligands	82
2.8	Chemicals	82
2.9	Instrumentation	83
2.10	Media for biocompatibility assays	84
2.11	Cell culture	85
2.12	Ethics statement	85
2.13	Animal models	86
2.14	Ligand synthesis	87
2.15	UV-Vis and potentiometric studies	95
2.16	Haemolysis assay	95
2.17	MTT assay	96
2.18	Production of ¹¹ C and ^{99m} Tc radioisotopes	97
2.18.1	Radiosynthesis of ¹¹ C as ¹¹ CH ₃ I	97
2.18.1	Radiosynthesis of ^{99m} Tc as Na ^{99m} TcO ₄	97
2.19	Radiolabelling	98
2.19.1	¹¹ C-labelling of compound 5	98

2.19.2	Radiolabelling of compounds 7, 10 and 11 with Na ^{99m} TcO ₄ (or ^{99m} TcO ₄ ⁻)	98
2.19.3	Radiochemical purity of ^{99m} Tc-labelled radio-complexes	99
2.19.4	Optimization of radiolabelling parameters for ^{99m} Tc-labelled radio-complexes	100
2.20	Determination of octanol-water partition coefficient (log P _{o/w})	100
2.21	Human serum stability test	101
2.22	Cysteine challenge test	102
2.23	Blood kinetics evaluation	102
2.24	<i>In vivo</i> SPECT imaging	102
2.25	Biodistribution studies	103
2.26	Regional brain uptake evaluation	104
2.27	References	104
Chapter 3: Development of 3D-Homology Models And Validation		
Part A:	Homology Modeling of Monomeric 5-HT_{1A} Receptor	109
3.1	Methodology developed	111
3.2	Results and discussion	113
3.2.1	Template selection, alignment and model building	113
3.2.2	Structural quality analysis	114
3.2.3	Identification of binding site	116
3.2.4	Ligand based screening	118
3.2.5	Virtual screening efficiency, stability and structural insight	122
3.2.6	Corroboration between <i>in silico</i> and <i>in vitro</i> studies	135
3.3	Conclusions	136
Part B:	Development of Monomeric 5-HT₇ Receptor Homology Model	138
3.4	Methodology	139

3.5	Results and discussion	141
3.5.1	Model variables	141
3.5.2	RP and structural quality analysis	143
3.5.3	Binding site analysis and docking with native ligand SB-269970	146
3.5.4	Ligand based screening	147
3.5.5	Embrace minimization	156
3.5.6	Structure-based ligand screening efficiency (SBLSE)	159
3.5.7	MD simulations	159
3.6	Conclusions	167
3.7	References	168
Chapter 4: Dimeric 5-HT_{1A} & 5-HT₇ Receptor Systems: Homo And Heterodimeric Model Generation		
4.1	Method development	185
4.2	Results and discussion	187
4.2.1	Generation of dimeric models	188
4.2.2	Orientation and dimer interface	190
4.2.3	Structure-quality validation	194
4.2.4	Refinement	201
4.2.5	Extended application	210
4.3	Conclusions	219
4.4	References	220
Chapter 5: Design of Mixed Affinity Based Neuroimaging Probes		
5.1	Pharmacophore selection	228
5.1.1	Monovalent mixed affinity ligand	228
5.1.2	Bivalent mixed affinity ligand	236

5.2	Results and discussion	242
5.2.1	Ligand binding analysis: docking studies	242
5.2.1.1	Monovalent ligands with monomeric 5-HT _{1A} /5-HT ₇ receptors	242
5.2.1.2	BTZ-based bivalent ligand with dimeric 5-HT _{1A} /5-HT ₇ receptors	243
5.2.1.3	Acetyl variants of BTZ-based bivalent ligand with dimeric 5-HT _{1A} /5-HT ₇ receptors	243
5.2.2	Receptor-ligand interaction analysis	245
5.2.2.1	Monovalent ligands	245
5.2.2.2	Bivalent ligands	251
5.2.3	Physicochemical evaluation	265
5.2.4	Dynamic stability of receptor-ligand complexes	284
5.3	Conclusions	289
5.4	References	289
Chapter 6:	Ligand Synthesis, Radiolabeling, Bio-Evaluation and Pre-Clinical Studies	
6.1	Results and discussion	301
Part A:	Development of Radioligands	301
6.1.1	Synthesis	301
6.1.2	Physiochemical characterization	307
6.1.2.1	UV-Vis spectroscopy	307
6.1.2.2	Potentiometric titrations	309
6.1.3	Radiolabelling	309
Part B:	Bio-Evaluation and Preclinical Studies	316
6.1.4	Biocompatibility	316
6.1.4.1	Haemolysis assay	316

6.1.4.2	Cytotoxicity assay	318
6.1.5	<i>In vitro</i> stability	320
6.1.5.1	Human serum stability test	320
6.1.5.2	Cysteine challenge test	320
6.1.6	Blood Brain Barrier (BBB) permeability	321
6.1.7	Pre-clinical evaluations	323
6.1.7.1	<i>In vivo</i> SPECT imaging	323
6.1.7.2	<i>In vivo</i> blood kinetics experiment	327
6.1.7.3	CORT treated chronic stress/depression model	329
6.1.7.4	<i>Ex vivo</i> biodistribution studies	331
6.1.7.5	Regional brain uptake studies	341
6.2	Conclusions	353
6.3	References	353
Chapter 7: Summary		
7.1	Advantage of CADD	361
7.2	Lead molecules for brain imaging	365
7.3	Organic versus metallic radionuclides and PET versus SPECT for neuroimaging	365
7.4	Limitations	371
7.5	Failure and merit	371
7.6	Future aspects and scope of thesis	372
	Bio-Data	373
Annexure 1: Supporting Information in CD.		

LIST OF FIGURES

Figure No.	Description	Page No.
Figure 1.1	Various types of imaging modalities used for brain imaging	2
Figure 1.2	Schematic of PET Scan	4
Figure 1.3	Schematic of SPECT Scan	6
Figure 1.4	Schematic of homology modeling technique	14
Figure 1.5	Schematic of LGICs	17
Figure 1.6	Schematic of GPCRs	18
Figure 1.7	Structure representations of GPCRs. (a) cylindrical representation with numbering of helices from I to VII and (b) cartoon representation with ligand-binding domain. The N- and C-terminus are labelled as N-term and C-term, 7-TMHs are labelled from I to VII, the ICLs and ECLs are labelled as ICL1-3 and ECL1-3 respectively. The regions of extracellular, transmembrane extracellular, transmembrane intracellular and intracellular of plasma membrane are labelled as EC, TM-EC, TM-IC and IC respectively. A short helix (H8, Lys311-Cys322) formed between TMH7 and C-term is labelled as VIII. The most conserved residues among GPCRs namely D134(E134)R135Y136 (TMH3), W265×P267 (TMH5) and N302P303××Y306 (TMH7) are marked blue and the disulphide bond Cys110-Cys187 in ECL region is shown as ball (gray) and stick (green) representation respectively (N: Asparagine; P: Proline; Y: Tyrosine; D: Aspartic acid; E: Glutamic acid; R: Arginine; W: Tryptophan; numbers alongside one letter abbreviation of residues represent the corresponding numbering of amino acids in sequence)	19
Figure 1.8	Schematic of HPA axis (top left) in physiological (top right) and DAS disorders (bottom). In the cases of psychiatric impairments, particularly DAS disorders, there occurs a dysregulation or abnormal functioning of glucocorticoid signalling with the sensitized negative feedback of HPA axis. This altered feedback from the adrenal gland to the pituitary and hypothalamus results in the increment of CRH and the blunted ACTH responses to CRH causing an elevated cortisol secretion	27
Figure 1.9	Effective antidepressants and anxiolytics targeting 5-HT _{1A} and 5-HT ₇ receptors	31

Figure 1.10	Constituents of a radiopharmaceutical agent	33
Figure 1.11	Mechanism of direct labeling of tyrosine residue of a BM via electrophilic substitution of radioiodine	35
Figure 1.12	Mechanism of indirect labeling of BM with metallic radionuclide (Nu: acting as a nucleophile) using BFC	36
Figures 1.13	Functional groups used as BFCs	37
Figure 1.14	The structure of various BFCs used in radiopharmaceutical development.	38
Figure 1.15	The schematic of radioactive decay of ^{11}C -radioisotope	39
Figure 1.16	Radio-synthesis of $^{11}\text{CO}_2$ and commonly used reactive ^{11}C -labelled precursors	40
Figure 1.17	Radio-synthesis of $^{11}\text{CH}_3\text{I}$ using wet chemistry method	41
Figure 1.18	Radio-synthesis of $^{11}\text{CH}_3\text{I}$ using gas chemistry method	41
Figure 1.19	Structures of clinically used ^{11}C -PET radiopharmaceuticals	42
Figure 1.20	Clinically used ^{11}C -PET radiopharmaceuticals	43
Figure 1.21	Schematic representation of the decay of $^{99\text{m}}\text{Tc}$ to the stable ^{99}Tc and ^{99}Ru	44
Figure 1.22	The schematic of a $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$ generator	45
Figure 1.23	The variable oxidation state obtained in the reduction of $^{99\text{m}}\text{TcO}_4^-$	45
Figure 1.24	Reduction of $^{99\text{m}}\text{TcO}_4^-$ and radio-complexation with a chelate	46
Figure 1.25	Modifications of $^{99\text{m}}\text{Tc}$ -core	46
Figure 1.26	$^{99\text{m}}\text{Tc}$ -based brain perfusion agents	47
Figure 1.27	$^{99\text{m}}\text{Tc}$ -based diagnostic radiopharmaceuticals	48
Figure 1.28	$^{99\text{m}}\text{Tc}$ -based radiopharmaceuticals for diagnostic imaging	49

Figure 3.1	Schematic representation of the methodology developed for the generation and validation of h5-HT _{1A} R homology model	112
Figure 3.2	Ligands employed for analysing virtual screening efficiency of models (2, 4, 6, 10 and 12)	119
Figure 3.3	The correlation plots obtained in ligand based screening using docking: (a) model 2, (b) model 4, (c) model 6, (d) model, (e) model 12, Embrace Minimization (f) model 2 and MM-GBSA (g) model 2	120
Figure 3.4	The sequence of most promising homology model (model 6). The residues highlighted in black boxes are in accordance with the reported literature, ensuring the generation of a reliable 3D-model for 5-HT _{1A} receptor	121
Figure 3.5	Agonists taken for the evaluation of screening efficiency analysis of model 6	125
Figure 3.6	Antagonists taken for the evaluation of screening efficiency analysis of model 6	126
Figure 3.7	Virtual screening efficiency of model 6 before and after the MD simulations	127
Figure 3.8	The RMSD plots of (a) AGT (XAI) and (b) ANGT (MPPI) protein-complexes of model 6 obtained during the production run of 60 ns	128
Figure 3.9	Superimposition of the docked (blue) and Post-MD (pink) ligand conformations of AGT and ANGT protein-complexes	129
Figure 3.10	Superimposition of docked (marine blue), native (splitpea green) and Post-MD (warm pink) protein-complexes of (a) AGT and (b) ANGT	130
Figure 3.11	Orientation of AGT (A) and ANGT (B) during the production run of 60 ns, where the whole production run was sequentially clustered at 10 ns intervals for each protein-ligand complex	132
Figure 3.12	Conformational changes occurred in the overall structure of the AGT bound protein-complex during the entire production run of 60 ns	133
Figure 3.13	The conformational changed occurred in the ANGT bound protein-complex during the course of 60 ns MD simulation	134

Figure 3.14	Corroboration established between in silico and in vitro studies for AGTs	135
Figure 3.15	Corroboration established between in silico and in vitro studies for ANGTs	135
Figure 3.16	The workflow for model generation and validation	140
Figure 3.17	Ligands considered for screening of models in ligand based screening	148
Figure 3.18	The correlation plots of (a) model 1 (b) model 2 and (c) model 6 in Ligand based screening. The models 1 and 6 produced low correlation coefficient values of 0.40 and 0.30 respectively, whereas 0.80 was obtained for model 2. The value of $R^2 = 0.80$ for model 2, indicated promising structural quality of this model for 5-HT ₇ receptor	152
Figure 3.19	Sequence of the best homology model (model 2) of h5-HT ₇ R. The presence of conserved residues are highlighted in black rectangular boxes	153
Figure 3.20	The 2D and 3D-ligand interaction diagrams and respective orientation of LP-211 in active site of model 2. The 2D-ligand interaction diagram shown in left corresponded to the pose with highest GScore in GlideXP docking. The conserved residues are highlighted in 3D-ligand interaction diagram (LID) shown in the top right corner. The orientation of LP-211 in the binding pocket of receptor has been shown in box highlighted in the bottom right corner of the figure. The side chain residues Asp162, Arg367 and Thr141 were found to interact through H-bonding with the protonated quaternary N-atom and the proton of the amidic linkage of LP-211. Phe343 and Phe344 interact hydrophobically through the two phenyl ring of the piperazine moiety	154
Figure 3.21	The 2D and 3D-LIDs and respective ligand orientation of SB-269970 in the active site of model 2. The ligand formed H-bond with the side chain amino acid residues Asp162 and Arg350. The top right corner shows the presence of conserved residues and the ligand orientation corresponding to the pose having maximum GScore values is shown in the bottom right corner of the figure	155

Figure 3.22	The 2D and 3D-LIDs and the respective orientation of LP-44 in active site of model 2. The 2D-LID shows that the phenyl ring of 2-Methoxy-phenylpiperazine moiety is involved in the hydrophobic interactions with the side chain residues Phe344 and Phe343. Additionally, the residue Arg367 was found to interact through hydrophobic as well as π -cation interactions with the fused benzene ring attached to amidic linkage of LP-44. The conserved residues found in the model with this ligand are highlighted in the top right corner, whereas the respective orientation corresponding to the interacting pose with highest GScore is shown in bottom right corner of the figure	155
Figure 3.23	The 2D and 3D-LIDs and respective orientation of DR-4004 in the active site of model 2. This orientation corresponds to the interacting pose with highest GScore. The two dimensional ligand interaction diagram is shown in the left corner. The residues Phe158, Asp162, Gln235 and Ser243 interact via H-Bonding with the proton of protonated quaternary amine, carbonyl oxygen and the proton of cyclic amide. Hydrophobic interaction was seen with the Phe344 with the fused benzene ring of the cyclic amide system. The 3D-ligand interaction diagram shown in top right corner highlights the presence of conserved side chain residues in the model. The bottom right corner depicts the spatial orientation of the ligand in the binding pocket of the model 2	156
Figure 3.24	The 2D and 3D-LIDs and the respective orientation of UCM-5600 in the active site of model 2. This ligand orientation corresponds to the pose with highest GScore. The 2D-ligand interaction diagram in the left side of the figure shows the H-bond formation of the proton attached to the protonated N-atom of the piperazine moiety with the residue Asp162. The residue Arg367 was found to interact via both the hydrophobic as well as π -cation interactions. The other significant residues found in the active site of the model 2 and the pose with highest GScore are shown in the top and bottom right side of the figure	157
Figure 3.25	Correlation obtained in Embrace Minimization study of model 2	157
Figure 3.26	The structure of (a) agonists and (b) antagonists used in SBLSE analysis of model 2	162
Figure 3.27	Comparative correlation of agonist and antagonist binding mode for model 2 in SBLSE analysis	163

Figure 3.28	The RMSD (a), (b) and (c) and the RMSF plots (d), (e) and (f) of modelled protein in M_F (ligand-free model), M_{ANTAG} (antagonist SB-29970) and M_{AGO} (agonist LP-211) complexes during the production run of 20 ns	164
Figure 3.29	The secondary structure elements (SSEs) as predicted from simulation interaction diagram (SID) of 20 ns MD simulation of (a) M_F , (b) M_{ANTAG} and (c) M_{AGO} complexes. The top subgraphs of figures 3.29(a-c) indicated that the alpha helices and beta strands were least fluctuated during the simulation	165
Figure 3.30	The ligand interaction and the H-bond interactions of the model complexes with (a, b) antagonist SB-29970 and (c, d) agonist LP-211 in MD simulation of 20 ns	166
Figure 4.1	The pictorial representative of the formation of potential gradient between 5-HT _{1A} -5-HT _{1A} homodimer and 5-HT _{1A} -5-HT ₇ heterodimer receptor systems. The post-synaptic concentration of 5-HT _{1A} -5-HT ₇ heterodimer increases under depression/stress, while the post synaptic concentration of 5-HT _{1A} -5-HT _{1A} homodimer decreases. On the other hand, reverse has been noticed under physiological condition, in which the post-synaptic concentration of 5-HT _{1A} -5-HT _{1A} homodimer is higher than that of 5-HT _{1A} -5-HT ₇ heterodimer. This concentration gradient developed under pathological conditions, diminishes the internalization of 5-HT _{1A} receptors, and thereby impairs the natural neuron firing leading to neurological disorders	184
Figure 4.2	The schematic of methodology developed for the generation of dimeric models of h5-HT _{1A} and h5-HT ₇ receptors	186
Figure 4.3	Various interfaces encountered for dimeric models during protein-protein docking	189
Figure 4.4	The quality assessment analysis plot of the best scored models of (a) 5-HT _{1A} -5-HT _{1A} (B1A1A-1), (b) 5-HT ₇ -5-HT ₇ (G77-3) and (c) 5-HT _{1A} -5-HT ₇ (G1A7-3) dimeric receptors using ProTSAV	195
Figure 4.5	The quality assessment analysis plot of (a) 4GPO: TM1/H8 interface (experimental model) and (b) 1N3M: Chain C-Chain E-TM1/H8 interface (theoretical model) of dimeric GPCRs using ProTSAV	196
Figure 4.6	The quality assessment analysis plot of 4GPO based preliminary homodimeric models of (a) 5-HT _{1A} -5-HT _{1A} and (b) 5-HT ₇ -5-HT ₇ receptors using ProTSAV	197

Figure 4.7	(a) Ramachandran plot and (b) packing efficiency analysis of model B1A1A-1 using RAMPAGE and VADAR	198
Figure 4.8	(a) Ramachandran plot and (b) packing efficiency analysis of model G77-3 using RAMPAGE and VADAR	199
Figure 4.9	(a) Ramachandran plot and (b) packing efficiency analysis of model G1A7-3 using RAMPAGE and VADAR	200
Figure 4.10	Analysis of 100 ns MD simulations of the dimeric models (a) B1A1A-1 (b) G77-3 and (c) G1A7-3 . The RMSD plots of model B1A1A-1 , G77-3 and G1A7-3 were truncated at 50, 60 and 40 ns respectively as the local minima were attained during these time frames of the production run	202
Figure 4.11	Superimposition of (a) native B1A1A-1 model (red) on 4GPO (marine blue) and (b) refined B1A1A-1 model (smudge green) on 4GPO (blue)	203
Figure 4.12	Superimposition of (a) native B1A1A-1 model (red) and (b) refined B1A1A-1 model (smudge green) on 1N3M (cyan)	204
Figure 4.13	Superimposition of (a) native G77-3 model (red) on 4GPO (marine blue) and (b) refined G77-3 model (purple slate blue) on 4GPO (blue)	205
Figure 4.14	Superimposition of (a) native G77-3 model (red) and (b) refined G77-3 model (purple slate blue) on 1N3M (cyan)	206
Figure 4.15	Superimposition of (a) native G1A7-3 model (red) on 4GPO (marine blue) and (b) refined G1A7-3 model (magenta light pink) on 4GPO (blue)	207
Figure 4.16	Superimposition of (a) native G1A7-3 model (red) and (b) refined G1A7-3 model (magenta light pink) on 1N3M (cyan)	208
Figure 4.17	Quality assessment analysis plot of the refined dimeric models (a) B1A1A-1 (b) G77-3 and (c) G1A7-3 using ProTSAV	209
Figure 4.18	Superimposition of (a) native B1A1A-1 model (red) and (b) refined B1A1A-1 model (smudge green) on 4GPO based preliminary 5-HT _{1A} -5-HT _{1A} homodimeric model (green)	211
Figure 4.19	Superimposition of (a) native G77-3 model (red) and (b) refined G77-3 model (purple slate blue) on 4GPO based preliminary 5-HT ₇ -5-HT ₇ homodimeric model (green)	212

Figure 4.20	Superimposition of (a) native B1A1A-1 (yellow-wheat) on native G77-3 (purple blue) and (b) refined B1A1A-1 (smudge green) on refined G77-3 (purple slate blue)	215
Figure 4.21	Superimposition of (a) native B1A1A-1 (yellow-wheat) on native G1A7-3 (red) and (b) refined B1A1A-1 (smudge green) on refined G1A7-3 (magenta light pink)	216
Figure 4.22	Superimposition of (a) native G77-3 (purple blue) on G1A7-3 native (red) and (b) refined G77-3 (purple slate blue) on refined G1A7-3 (magenta light pink)	217
Figure 4.23	Superimposition of (a) native B1A1A-1 (red) on refined B1A1A-1 (smudge green) and (b) native G77-3 (red) on refined G77-3 (purple slate blue)	218
Figure 4.24	Superimposition of (a) native G1A7-3 (red) on refined G1A7-3 (magenta light pink)	219
Figure 5.1	Hybrid ligands reported for mapping 5-HT _{1A} and 5-HT ₇ receptors	230
Figure 5.2	CNS active ligands referred to ensure pharmacophore selection	233
Figure 5.3	CNS active ligands referred to ensure pharmacophore selection	234
Figure 5.4	The structure of mixed affinity based hybrid ligand (BTZ-MPP)	235
Figure 5.5	Structure of designed bivalent ligand (BTZ) ₂ DTPA	238
Figure 5.6	Structure of 3,6-disubstituted benzothiazolone derivatives reported for 5-HT _{1A} (B, C) , 5-HT ₆ (E), D ₂ (B) and σ_1 (A, C, D) receptors	239
Figure 5.7	Structure of acetyl substituted (BTZ) ₂ DTPA based bivalent ligands	240
Figure 5.8	The LIDs of CH ₃ -BTZ-MPP in the active site of monomeric 5-HT _{1A} and 5-HT ₇ receptors	248
Figure 5.9	The LIDs of F-Ph-ppyn-BTZ-MPP in the active site of monomeric 5-HT _{1A} and 5-HT ₇ receptors	249
Figure 5.10	The LIDs of DTC-BTZ-MPP in the active site of monomeric 5-HT _{1A} and 5-HT ₇ receptors	252

Figure 5.11	The 2D and 3D-LIDs of (BTZ) ₂ DTPA with homodimeric 5-HT _{1A} -5-HT _{1A} receptor	255
Figure 5.12	The 2D and 3D-LIDs of (BTZ) ₂ DTPA with homodimeric 5-HT ₇ -5-HT ₇ receptor	257
Figure 5.13	The 2D-LIDs of (BTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	258
Figure 5.14	The 3D-LIDs of (BTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	259
Figure 5.15	The 2D and 3D-LIDs of (7-AcBTZ) ₂ DTPA with homodimeric 5-HT _{1A} -5-HT _{1A} receptor	266
Figure 5.16	The 2D and 3D-LIDs of (7-AcBTZ) ₂ DTPA with homodimeric 5-HT ₇ -5-HT ₇ receptor	267
Figure 5.17	The 2D-LIDs of (7-AcBTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	268
Figure 5.18	The 3D-LIDs of (7-AcBTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	269
Figure 5.19	The 2D and 3D-LIDs of (6-AcBTZ) ₂ DTPA with homodimeric 5-HT _{1A} -5-HT _{1A} receptor	270
Figure 5.20	The 2D and 3D-LIDs of (6-AcBTZ) ₂ DTPA with homodimeric 5-HT ₇ -5-HT ₇ receptor	271
Figure 5.21	The 2D-LIDs of (6-AcBTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	272
Figure 5.22	The 3D-LIDs of (6-AcBTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	273
Figure 5.23	The 2D and 3D-LIDs of (5-AcBTZ) ₂ DTPA with homodimeric 5-HT _{1A} -5-HT _{1A} receptor	274
Figure 5.24	The 2D and 3D-LIDs of (5-AcBTZ) ₂ DTPA with homodimeric 5-HT ₇ -5-HT ₇ receptor	275
Figure 5.25	The 2D-LIDs of (5-AcBTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	276
Figure 5.26	The 3D-LIDs of (5-AcBTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	277

Figure 5.27	The 2D and 3D-LIDs of (4-AcBTZ) ₂ DTPA with homodimeric 5-HT _{1A} -5-HT _{1A} receptor	278
Figure 5.28	The 2D and 3D-LIDs of (4-AcBTZ) ₂ DTPA with homodimeric 5-HT ₇ -5-HT ₇ receptor	279
Figure 5.29	The 2D-LIDs of (4-AcBTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	280
Figure 5.30	The 3D-LIDs of (4-AcBTZ) ₂ DTPA within the 5-HT _{1A} and 5-HT ₇ pockets of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	281
Figure 5.31	The shortlisted high affinity ligands using GlideXP docking studies	282
Figure 5.32	RMSD plots of receptor-ligand complexes of monovalent ligands 1 , 2 and 3 with 5-HT _{1A} receptor (a, c, e) and 5-HT ₇ receptors (b, d, f) during the production run of 40 ns (a, b, e), 50 ns (d), 75 ns (f) and 80 ns (c) respectively. Each production run was initially run for 100 ns, which later was truncated to the respective time-frame for achieving the local minima, consequently the stability acquired by each receptor-ligand complexes	286
Figure 5.33	RMSD plots of receptor-ligand complexes of bivalent ligands 4 and 5 with 5-HT _{1A} -5-HT _{1A} receptor (a, b), 5-HT ₇ -5-HT ₇ (c, d) 5-HT _{1A} -5-HT ₇ (c, d) receptors during MDs run of 100 ns (a, b, e), 80 ns (c, d) and 60 ns (f) respectively. Each production run was initially run for 100 ns, which later was truncated to the respective time-frame for achieving the local minima, consequently the stability acquired by the system	287
Figure 6.1	Structures of lead molecules taken for research and development	301
Figure 6.2	HPLC profile of compound 5 (synthon)	304
Figure 6.3	HPLC profile of compound 6 . Cold methylation was achieved using aq. NaOH in water-THF (1:1) as the reaction medium	304
Figure 6.4	HPLC profile of compound 6 . Cold methylation was successfully achieved using ethanolic NaOH in absolute ethanol as the solvent system	305

Figure 6.5	Confirmation of cold methylation of compound 5 with CH ₃ I through HPLC. Cold labelled compound (6) was mixed with synthon (compound 5) which gave two distinct peaks at 4.9 and 6.4 min respectively	305
Figure 6.6	The UV-Vis characterization of (a) CH ₃ -BTZ-MPP, (b) DTC-BTZ-MPP, (c) (BTZ) ₂ DTPA and (d) (6-AcBTZ) ₂ DTPA ligands	308
Figure 6.7	The HPLC profile of crude [¹¹ C]-BTZ-MPP (I) radioligand	313
Figure 6.8	The HPLC profile of a mixture of crude [¹¹ C]-BTZ-MPP (I) radioligand and synthon	314
Figure 6.9	HPLC profile of purified [¹¹ C]-BTZ-MPP (I)	314
Figure 6.10	Optimization of radiolabelling parameters of [^{99m} Tc]-DTC-BTZ-MPP (II): (a) radiolabelling efficiency in saline, effect of (b) stannous chloride concentration, (c) pH and (d) incubation time	315
Figure 6.11	Optimization of radiolabelling parameters of [^{99m} Tc]-(BTZ) ₂ DTPA (III): (a) radiolabelling efficiency in saline, effect of (b) stannous chloride concentration, (c) pH and (d) incubation time	315
Figure 6.12	Optimization of radiolabelling parameters of [^{99m} Tc]-(6-AcBTZ) ₂ DTPA (IV): (a) radiolabelling efficiency in saline, effect of (b) stannous chloride concentration, (c) pH and (d) incubation time	316
Figure 6.13	Haemolysis assay of radioligands: (a) I , (b) II , (c) III and (d) IV	317
Figure 6.14	MTT assay of synthesized ligands: (a) I , (b) II , (c) III and (d) IV	319
Figure 6.15	In vitro stability evaluation of ^{99m} Tc-labelled radio-complexes in human serum and cysteine challenge tests. Observed percentage radiolabelling efficiency of radioligands: (a, b) II , (c, d) III and (e, f) IV in human serum and with varying cysteine concentration	321

Figure 6.16	The non-invasive in vivo imaging observations of [^{99m}Tc]-DTC-BTZ-MPP (II): (a) in vivo dynamic SPECT images TACs of (b) brain, (c) heart and lungs, (d) liver and (e) kidney obtained after 30 min p.i. of radioligand II . The dynamic SPECT images acquired at different time intervals and various TACs suggested significant radioactivity retention in brain followed by a gradual decline. Similar trend in heart, lungs and liver. The trend was observed for heart, lungs and liver. However, an increase in activity was spotted in kidney indicating along with a slow drop in radioactivity accumulation in liver indicated a combination of hepatobiliary and renal mode of excretion for the radioligand. The radioligand was injected intravenously in a normal New Zealand rabbit (n = 1) and the images were acquired dynamically at different time intervals. The insight images in the TACs depicts the ROI adopted for determining the decay in activity with respect to time as counts/sec and was plotted against the time of acquisition time dynamic scans	325
Figure 6.17	The whole body dynamic anterior SPECT images of normal New Zealand rabbit (n = 1) acquired after 5 min post administration of ^{99m}Tc -(BTZ) $_2$ DTPA. The images show brain uptake followed by subsequent washout	326
Figure 6.18	The (a) whole body dynamic SPECT scan and (b) brain time-activity curve of [^{99m}Tc]- (6-AcBTZ) $_2$ DTPA radioligand. Insight in TAC represents the region chosen for time-dependent activity decay calculations	327
Figure 6.19	Pharmacokinetics of metal labelled radioligands: (a) [^{99m}Tc]-DTC-BTZ-MPP (II), (b) [^{99m}Tc]- (BTZ) $_2$ DTPA (III) and (c) [^{99m}Tc]- (6-AcBTZ) $_2$ DTPA (IV)	328
Figure 6.20	Analysis of depressogenic symptoms in CORT-injected animal models using: (a) body weight and (b) food intake measurements	330
Figure 6.21	The ex vivo biodistribution studies of [^{11}C]-BTZ-MPP (I) in (a) control and (b) model	334
Figure 6.22	The biodistribution studies of [^{99m}Tc]-DTC-BTZ-MPP (II) in (a) control and (b) model	337
Figure 6.23	The biodistribution studies of [^{99m}Tc]-DTC-BTZ-MPP (II) of control in (a) serotonin (SER) and (b) 2-methoxyphenylpiperazine (MPP)	338

Figure 6.24	The biodistribution studies of $^{99m}\text{Tc}-(\text{BTZ})_2\text{DTPA}$ (III). Insight: excretion route followed radiotracer analysed using dynamic SPECT scan of rabbit	340
Figure 6.25	The ex vivo biodistribution studies of radioligand IV	341
Figure 6.26	Regional brain uptake studies of [^{11}C]-BTZ-MPP (I) in (a) control, (b) model and (c) comparative total brain uptake in control and model	343
Figure 6.27	Regional uptake studies of [^{99m}Tc]-DTC-BTZ-MPP (II) in the post-mortem brain of female Balb/c mice. Blocking studies were performed against SER and MPP. The regional localization is represented as the comparative evaluation among animal groups of control, control + SER, control + MPP and model at (a) 5 min p.i. (b) 15 min p.i. and (c) 30 min p.i. respectively	348
Figure 6.28	Total brain uptake obtained in the regional distribution study of [^{99m}Tc]-DTC-BTZ-MPP (II)	349
Figure 6.29	Time activity curve of $^{99m}\text{Tc}-(\text{BTZ})_2\text{DTPA}$ in the brain regions of normal Balb/c female mice	349
Figure 6.30	(a) Regional localization and (b) regional selectivity studies of $^{99m}\text{Tc}-(6\text{-AcBTZ})_2\text{DTPA}$	351
Figure 7.1	The generated and validated homology models of 5-HT _{1A} and 5-HT ₇ receptors	362
Figure 7.2	3D-model of homodimeric 5-HT _{1A} -5-HT _{1A} receptor	363
Figure 7.3	3D-model of homodimeric 5-HT ₇ -5-HT ₇ receptor	364
Figure 7.4	3D-model of heterodimeric 5-HT _{1A} -5-HT ₇ receptor	364
Figure 7.5	Brain dissection of Balb/c female mice. (a) lateral view, (b) front view, (c and d) chronologically arranged slices of brain regions viz. cerebellum, cortex, hippocampus and striatum	367
Figure 7.6	Monovalent radioligands and their diagnostic application	368
Figure 7.7	Homobivalent $^{99m}\text{Tc}-(\text{BTZ})_2\text{DTPA}$ radioligand for targeted neuroimaging of dimeric 5-HT _{1A} /5-HT ₇ receptors	369
Figure 7.8	$^{99m}\text{Tc}-(6\text{-AcBTZ})_2\text{DTPA}$ neuroimaging tracer for mapping dimeric 5-HT _{1A} /5-HT ₇ receptors	370

LIST OF TABLES

Table No.	Description	Page No.
Table 1.1	Radionuclide used for PET and SPECT imaging	7
Table 1.2	General characteristics of PET and SPECT imaging modalities	8
Table 1.3	Difference between traditional drug design and CADD	11
Table 3.1	Homology obtained during BLAST search and alignment between query and template	113
Table 3.2	Ramachandra Plot analysis of generated models	116
Table 3.3	Structure analysis of generated models	117
Table 3.4	Interactions observed for shortlisted homology models of h5-HT _{1A} R	118
Table 3.5	Values of RMSDs obtained upon superimposing the docked, minimized and Post-MD protein-complexes of AGT and ANG1	127
Table 3.6	Angles measured for the deviation observed in the Pot-MD protein-complexes of AGT and ANG1	131
Table 3.7	Overview of reports for 5-HT ₇ R HM	139
Table 3.8	Parameters obtained before and after alignment for mono-, di- and multi-template approaches	142
Table 3.9	Ramachandran plot analysis of models using RAMPAGE, PROCHECK and MolProbity tools	144
Table 3.10	Quality analysis of models using PROVE, ERRAT, PROCHECK and WHATCHECK tools	145
Table 3.11	The essential amino acid residues reported for h5-HT ₇ R	147
Table 3.12	The amino acid residues and corresponding GScore values observed in the binding site of the generated models	149
Table 3.13	Interacting amino acid residues with the LP-211, SB-269970, LP-44, DR-4004 and UCM-5600 ligands	158

Table 3.14	The interactions observed in M _{ANTAG} and M _{AGO} complexes of the modelled protein in the MD simulations	167
Table 4.1	Number of models selected with parallel orientation	191
Table 4.2	Dimer interface observed in the resolved crystal structure of GPCRs	192
Table 4.3	Analysis of dimer interface of the selected models	193
Table 4.4	Screening of models using ProTSAV	194
Table 4.5	Structural corroboration of native and refined dimeric models with experimental/theoretical templates of GPCRs	201
Table 4.6	Structural corroboration of native and refined generated homodimeric models with 4GPO based preliminary homodimeric models	210
Table 4.7	Superimposition of modelled homo and heterodimeric proteins	214
Table 5.1	Experimental versus calculated log P _{o/w} of few CNS active drugs	232
Table 5.2	The calculated molecular distance of bivalent ligands	241
Table 5.3	Structure of designed monovalent and bivalent neuroimaging probes	242
Table 5.4	Docking results of monomeric ligands	244
Table 5.5	Docking results of dimeric ligands	245
Table 5.6	The receptor ligand interactions of monomeric ligands with monomeric 5-HT _{1A} receptor	250
Table 5.7	The receptor ligand interactions of monomeric ligands with monomeric 5-HT ₇ receptor	251
Table 5.8	The receptor-ligand interaction of (BTZ) ₂ DTPA with dimeric receptors	256
Table 5.9	The receptor-ligand interaction of (7-AcBTZ) ₂ DTPA with dimeric 5-HT _{1A} /5-HT ₇ receptors	260
Table 5.10	The receptor-ligand interaction of (6-AcBTZ) ₂ DTPA with dimeric 5-HT _{1A} /5-HT ₇ receptors	262

Table 5.11	The receptor-ligand interaction of (5-AcBTZ) ₂ DTPA with dimeric 5-HT _{1A} /5-HT ₇ receptors	263
Table 5.12	The receptor-ligand interaction of (4-AcBTZ) ₂ DTPA with dimeric 5-HT _{1A} /5-HT ₇ receptors	264
Table 5.13	ADME properties of designed ligands	283
Table 5.14	RMSD evaluation of the docked, minimized and post-MD receptor-ligand complexes	288
Table 6.1	Determination of protonation constants of (BTZ) ₂ DTPA and (6-AcBTZ) ₂ DTPA ligands (298 K)	309
Table 6.2	Notation of the developed radioligands and their neuroimaging applications	310
Table 6.3	Regional distribution of radioligand III in Balb/c female mice brain	350

LIST OF SCHEMES

Scheme No.	Description	Page No.
Scheme 6.1	Synthetic protocol of synthon: BTZ-MPP	302
Scheme 6.2	Synthetic scheme of cold-methylation and/or cold-labelling of synthon	303
Scheme 6.3	Synthesis of ligand 3: DTC-BTZ-MPP	306
Scheme 6.4	Synthesis of bivalent ligands	307
Scheme 6.5	Radiosynthesis of [$^{11}\text{CH}_3$]-BTZ-MPP (I)	311
Scheme 6.6	Radiosynthesis of [$^{99\text{m}}\text{Tc}$]-DTC-BTZ-MPP (II)	312
Scheme 6.7	Radiosynthesis of [$^{99\text{m}}\text{Tc}$]-(BTZ) ₂ DTPA (III)	312
Scheme 6.8	Radiosynthesis of [$^{99\text{m}}\text{Tc}$]-(6-AcBTZ) ₂ DTPA (IV)	313

GLOSSARY OF SYMBOLS AND ABBREVIATIONS

β^+	Positron
γ	Gamma
KeV	Kilo Electron Volt
MeV	Mega Electron Volt
$^{\circ}$	Degree (unit of Angle)
$^{\circ}\text{C}$	Degree Celsius (unit of Temperature)
$t_{1/2}$	Half-life
p	Proton
α	Alpha particle
n	Neutron
d	Deuteron
m_e	Mass of electron (9.109×10^{-31} kilograms)
c	Speed of light (2.998×10^8 m / s)
min	Minute
h	Hour
mm	Millimetre
M	mol L ⁻¹ (Unit of concentration, Molarity)
N	equivalents/L (Unit of concentration, Normality)
mM	Millmolar
nM	Nanomolar
pM	Picomolar
K_i	Inhibition Constant
pK _i	$-\log_{10}K_i$

vdW	Van der Waals
Å	Ångström (10^{-10} meter)
ns	Nanosecond
MHz	Mega Hertz
δ	Delta
ppm	Parts per million
J	Coupling Constant
K	Kelvin (Unit of temperature)
C α	Alpha-position of protein backbone
λ	Wavelength
nm	Nanometre (10^{-9} m)
μm	Micrometre (10^{-6} m)
v/v/v or v/v	Volume ratio
mL	Millilitre
g	Gram
L	Litre
g/l	Gram per litre
rpm	Revolutions per minute
i.v.	Intravenous
i.p.	Intraperitoneal
MBq	Megabecquerel (SI unit of radioactivity, $1 \text{ Bq} = 1 \text{ s}^{-1}$)
mCi	Millicurie (non-SI unit of radioactivity, $1 \text{ mCi} = 3.7 \times 10^{16}$ decays per second or Bq)
pH	Logarithmic scale of acidity or basicity in aqueous solution ($-\log_{10}[\text{H}^+]$)
R _f	Retention factor

G_{ai} , G_{ao} , G_{aq} , G_{as}	GDP-bound conformations of G-protein
Na^+/K^+	Sodium-Potassium pump
^{11}B , ^{14}N , ^{15}O	Naturally occurring Boron, Nitrogen, Oxygen
^{11}C , ^{18}F	Radioactive isotope of Carbon, Fluorine
^{99m}Tc	Radioactive metastable isotope of Technetium
^{111}In , ^{90}Y , ^{201}Tl	Radioactive isotope of Indium, Yttrium, Thallium
^{123}I , ^{131}I	Radioactive isotopes of Iodine
^{99}Mo , ^{177}Lu , ^{188}Rh	Radioactive isotope of Molybdenum, Lutetium, Rhodium
^{235}U , ^{68}Ga	Radioactive isotope of Uranium, Gallium
Kr	Krypton
Nu	Nucleophile
$LiAlH_4$	Lithium aluminium hydride
CH_3OTf	Methyl Triflate
Al_2O_3	Aluminium oxide
TcO_4^-	Pertechnetate
$NaBH_4$	Sodium borohydride
HCl	Hydrochloric acid
$SnCl_2$	Stannous chloride
NaI	Sodium iodide
SER	Serotonin Hydrochloride
MPP	2-Methoxyphenylpiperazine
BTZ	Benzothiazolone
$CHCl_3$	Chloroform
$CDCl_3$	Deuterated chloroform
MeOH	Methanol

DMF	Dimethylformamide
TEA	Triethylamine
TFA	Trifluoro acetic acid
TBAOH	Tetrabutylammonium Hydroxide
DMSO	Dimethyl sulfoxide
NaOH	Sodium hydroxide
Na ₂ CO ₃	Sodium carbonate
SG	Silica gel
NaCl	Sodium chloride
CO ₂	Carbon dioxide
XP	Extra Precision
2D	Two-Dimensional
3D	Three-Dimensional
CNS	Central Nervous System
WHO	World Health Organisation
GBD	Global Burden of Disease
CT	Computed Tomography
MRI	Magnetic Resonance Imaging
PET	Positron Emission Tomography
SPECT	Single Photon Emission Computed Tomography
PMTs	Photomultiplier tubes
BBB	Blood Brain Barrier
AD	Alzheimer's Disease
CADD	Computer Aided Drug Design
LBDD	Ligand Based Drug Design

SBDD	Structure Based Drug Design
QSAR	Quantitative Structure-Activity Relationship
NMR	Nuclear Magnetic Resonance
SSRIs	Selective Serotonin Reuptake Inhibitors
COX-2	Cyclooxygenase-2
NSAIDs	Nonsteroidal Anti-Inflammatory Drugs
HIV	Human Immunodeficiency Virus
HM	Homology Modeling
FASTA	Text-based representation of protein sequences by using single letter codes
BLAST	Basic Local Alignment Search Tool
PSI-BLAST	Position-Specific Iterative BLAST
G-protein	Guanine Nucleotide-Binding Protein
GPCRs	G-protein Coupled Receptors
MDs	Molecular Dynamic simulations
LGICs	Ligand-Gated Ion Channels
GABA	γ -Aminobutyric acid
TM	Transmembrane
TMD	Transmembrane Domain
TMH	Transmembrane Helix
ICL	Intracellular Loop
ECL	Extracellular Loop
5-HT	Serotonin
DA	Dopamine
NE	Norepinephrine

AC	Adenylate cyclase
cAMP	Cyclic adenosine monophosphate or 3',5'-cyclic adenosine monophosphate
5-HTRs	Serotonin receptors
h5-HT _{1A} R	human 5-HT _{1A} receptor
h5-HT ₇ R	human 5-HT ₇ receptor
5-HT ₁	Serotonin receptor subtype - 1
5-HT _{1A} R	Serotonin receptor subtype - 1A
5-HT _{1B} R	Serotonin receptor subtype - 1B
5-HT _{1D} R	Serotonin receptor subtype - 1D
5-HT _{1E} R	Serotonin receptor subtype - 1E
5-HT _{1F} R	Serotonin receptor subtype - 1F
5-HT _{2A} R	Serotonin receptor subtype - 2A
5-HT _{2B} R	Serotonin receptor subtype - 2B
5-HT _{2C} R	Serotonin receptor subtype - 2C
5-HT ₃ R	Serotonin receptor subtype - 3
5-HT ₄ R	Serotonin receptor subtype - 4
5-HT ₅ Rs	Serotonin receptor subtype - 5
5-HT _{5A} R	Serotonin receptor subtype - 5A
5-HT _{5B} R	Serotonin receptor subtype - 5B
5-HT ₆ R	Serotonin receptor subtype - 6
5-HT ₇ or 5-HT ₇ R	Serotonin receptor subtype - 7
5-HT _{1A} -5-HT _{1A}	Homodimer of serotonin receptor subtype - 1A
5-HT ₇ -5-HT ₇	Homodimer of serotonin receptor subtype - 7
5-HT _{1A} -5-HT ₇	Heterodimer of serotonin receptor subtypes - 1A and 7

D ₂	Dopamine receptor 2
mGluR5	Metabotropic glutamate receptor 5
β ₂ AR, β ₁ AR	human β ₂ -adrenergic receptor, β ₁ -adrenergic receptor
hA _{2A} R	human A _{2A} crystal structure
CBRs	Cannabinoid receptors
CCM	Consensus Cholesterol Binding Motif
4GPO	Oligomeric Turkey Beta1-Adrenergic G Protein-Coupled Receptor
1N3M	Theoretical model of Rhodopsin Oligomer
ADME	Adsorption, Distribution, Metabolism and Excretion
3D4S	Cholesterol bound human β ₂ -Adrenergic Receptor
2RH1	human β ₂ -adrenergic receptor
1F88	Bovine Rhodopsin
CA	cornu Ammon
CA1	cornu Ammon 1
CA3	cornu Ammon 3
Lys	Lysine
Cys	Cysteine
D, Asp	Aspartic acid
E, Glu	Glutamic acid
R, Arg	Arginine
Y, Tyr	Tyrosine
W, Trp	Tryptophan
P, Pro	Proline
N, Asn	Asparagine

Phe	Phenylalanine
Val	Valine
Thr	Threonine
Ile	Isoleucine
Ser	Serine
Gln	Glutamine
MAOI	Monoamine Oxidase Inhibitor
TCA	Tricyclic Antidepressant
FDA	Food and Development Administration
ADHD	Attention Deficit Hyperactivity Disorder
OCD	Obsessive Compulsive Disorder
MDD	Major Depressive Disorders
DAS	Depression, Anxiety and Stress
HPA	Hypothalamic-Pituitary-Adrenal
DSM	Diagnostic and Statistical Manual
PTSD	Post-Traumatic Stress Disorder
GAD	Generalized Anxiety Disorder
ACTH	Adrenocorticotrophic Hormone
CRF	Corticotrophic-Releasing Factors
CRH	Corticotrophic-Releasing Hormone
DST	Dexamethasone Suppression Test
mRNA	Messenger Ribonucleic Acid
CORT	Corticosterone
TH	Tyrosine Hydroxylase
FST	Forced Swim Test

TST	Tail Suspension Test
FT	Filed Test
PMT	Plus Maze Test
BM	Biomolecule
EMA	European Medicines Agency
BFCs	Bifunctional Chelating Agents
DTPA	Diethylenetriamine Pentaacetic Acid
EDTA	Ethylenediaminetetraacetic Acid
DFO	Desferrioxamine
H ₂ DEDPA	6,6'-((ethane-1,2-diylbis(azanediyl))bis(methylene))dipicolinic acid
AAZTA	2,2'-((1,4-bis(carboxymethyl)-6-methyl-1,4-diazepan-6-yl)azanediyl)diacetic acid
DOTA	2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid
TETA	2,2',2'',2'''-(1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrayl)tetraacetic acid
NOTA	2,2',2''-(1,4,7-triazonane-1,4,7-triyl)triacetic acid
THF	Tetrahydrofuran
CH ₃ OTf	Trifluoromethanesulfonate or triflate
SB-269970	3-[(2R)-2-[2-(4-Methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol
LATUDA	Trade name of Lurasidone
¹¹ C-PIB	N-Methyl-[¹¹ C]-2-(4'-methylaminophenyl)-6-hydroxybenzothiasole
¹¹ C-PMP	1-[¹¹ C]methylpiperidin-4-yl propionate
¹¹ C-NMSP	3-N-[¹¹ C]Methylpiperone

¹¹ C-WAY100635	[¹¹ C]N-(2-(4-(2-methoxyphenyl)-1-piperazin-1-yl)ethyl)-N-(2-pyridyl)cyclohexanecarboxamide
¹¹ C-MPEP	2-[¹¹ C]Methyl-6-(2-phenylethynyl)pyridine
15R- ¹¹ C-TIC	(15R)-16-m-[¹¹ C]tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester
¹¹ C-85380	3-[2(S)-2-Azetidinylmethoxy]pyridine
8-OH-DPAT	7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
DR-4004	1-[4-(4-Phenyl-3,6-dihydro-2H-pyridin-1-yl)-butyl]-2a,3,4,5-tetrahydro-1H-benzo[cd]indol-2-one
SB-269970	(R)-3-[2-[2-(4-Methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol hydrochloride
SB-258741	R-(+)-1-(toluene-3-sulfonyl)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine
SB-656104	6-((R)-2-{2-[4-(4-Chloro-phenoxy)-piperidin-1-yl]-ethyl}-pyrrolidine-1-sulphonyl)-1H-indole hydrochloride
LP-44	4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide hydrochloride
NAN-190	1-(2-methoxyphenyl)-4(4-(2-phthalimido)butyl)piperazine
F-15599	3-chloro-4-fluorophenyl-(4-fluoro-4-[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl)-piperidin-1-yl)-methanone
F-13640	(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone
F-13714	3-Chloro-4-fluorophenyl-(4-fluoro-4-[[[(5-methyl-4-methylamino-pyridin-2-ylmethyl)-amino]-methyl]-piperidin-1-yl)methanone
PRX-00023	N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide
WAY-101405	(R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide
WAY-100135	3-[4-(2-Methoxyphenyl)piperazin-1-yl]-2-phenyl-N-tert-butyl-propanamide dihydrochloride

SRA-333	4-cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-pyridin-2-ylbenzamide;hydrochloride
p-MPPF	4-Fluoro-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-2-pyridinylbenzamide
p-MPPI	4-Iodo-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylbenzamide
NAN-190	1-(2-Methoxyphenyl)-4-(4-phthalimidobutyl)piperazine hydrobromide
NAD-299	(3R)-3-(Dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrochloride
LY-426965	(2S)-1-Cyclohexyl-4-[4-(2-methoxyphenyl)-1-piperazinyl]-2-methyl-2-phenyl-1-butanone
MP-3022	4-(3-(Benzotriazol-1-yl)propyl)-1-(2-methoxyphenyl)piperazine
(S)-UH-301	(S)-5-fluoro-8-hydroxy-2-(dipropylamino)-tetralin [(S)-UH-301
BMV-7378	8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione
LP-211	N-[(4-cyanophenyl)methyl]-6-[4-(2-phenylphenyl)piperazin-1-yl]hexanamide
UCM-5600	1-[5-(4-phenylpiperazin-1-yl)pentyl]benzo[cd]indol-2-one
LP-12	6-[4-(2-phenylphenyl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide
CW	ClustalW
PSTA	Prime-Single Template Alignment
KB	Knowledge Based
EB	Energy Based
SGB	Surface Generalized Born
PDB	Protein Data Bank
LIDs	Ligand Interaction Diagrams

RMSD	Root Mean Square Deviation
RMSF	Root Mean Square Fluctuation
SSEs	Secondary Structure Elements
TMS	Tetramethylsilane
MBAE	Multi-Ligand Bimolecular Association with Energetics
NVT	Constant Temperature and Volume
NPT	Constant Temperature and Pressure
ITLC	Instant Thin Layer Chromatography
HPLC	High Performance Liquid Chromatography
MTT	3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide
PAW	Pyridine/Acetic acid/Water
DMEM	Dulbecco's Modified Eagle's Medium
HEPES	2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
α -MEM	Minimum Essential Medium
PBS	Phosphate Buffer Saline
FBS	Fetal Bovine Serum
HEK-293	Human Embryonic Kidney Cells
RBCs	Red blood cells
OD	Optical Density
BALB/c	Albino, Laboratory-bred strain of the house mouse
CPCSEA	Committee for the Purpose of Control and Supervision of Experiments on Animals
IAEC	Institutional Animal Ethics Committee
BRIT	Board of Radiation and Isotope Technology
DAE	Department of Atomic Energy